Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma

Kazunori Nakaoka, Eizaburo Ohno, Naoto Kawabe, Teiji Kuzuya, Kohei Funasaka, Yoshihito Nakagawa, Mitsuo Nagasaka, Takuya Ishikawa, Ayako Watanabe, Takumi Tochio, Ryoji Miyahara, Tomoyuki Shibata, Hiroki Kawashima, Senju Hashimoto, Yoshiki Hirooka

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Pancreatic ductal adenocarcinoma (PDAC) can be treated with surgery, chemotherapy, and radiotherapy. Despite medical progress in each field in recent years, it is still insufficient for managing PDAC, and at present, the only curative treatment is surgery. A typical pancreatic cancer is relatively easy to diagnose with imaging. However, it is often not recommended for surgical treatment at the time of diagnosis due to metastatic spread beyond the pancreas. Even if it is operable, it often recurs during postoperative follow-up. In the case of PDAC with a diameter of 10 mm or less, the 5-year survival rate is as good as 80% or more, and the best index for curative treatment is tumor size. The early detection of pancreatic cancer with a diameter of less than 10 mm or carcinoma in situ is critical. Here, we provide an overview of the current status of diagnostic imaging features and genetic tests for the accurate diagnosis of early-stage PDAC.

Original languageEnglish
Article number215
Issue number2
Publication statusPublished - 01-2023

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry


Dive into the research topics of 'Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma'. Together they form a unique fingerprint.

Cite this